Dudediligence.

Myriad Genetics, Inc

MYGNNASDAQ · In Vitro & in Vivo Diagnostic Substances
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$213.3MSep ’24$210.6MDec ’24$195.9MMar ’25$213.1MJun ’25$205.7MSep ’25$209.8MDec ’25$200.4MMar ’26$190.7MJun ’26
Net income, by quarter
−$22.1MSep ’24−$42.5MDec ’24−$100,000Mar ’25−$330.5MJun ’25−$27.4MSep ’25−$7.9MDec ’25−$34.1MMar ’26−$43.2MJun ’26
Fiscal years, by the month each ended
LineDec 2022Dec 2023Dec 2024Dec 2025Jun 2026
Revenue$678.4M$753.2M$837.6M$824.5Mnone on file
Gross profit$476.4M$517.0M$585.4M$576.6Mnone on file
Operating income−$140.6M−$257.4M−$123.5M−$387.2Mnone on file
Net income−$112.0M−$263.3M−$127.3M−$365.9Mnone on file
Operating cash flow−$106.3M−$110.9M−$8.7M$1.8Mnone on file
Free cash flow−$151.6M−$174.1M−$27.7M−$13.8Mnone on file
Cash$56.9M$132.1M$102.4M$149.6M$115.2M
Debt$0.00$38.5M$39.6M$119.9M$120.7M
Shares outstanding81.2M89.9M91.3M93.5M95.6M